麦澜德（688273）：耗材业务快速增长，积极布局潜力赛道

Investment Rating - The investment rating for the company is "Buy" (maintained) due to rapid growth in consumables business and proactive layout in potential sectors [5][6]. Core Views - The company is expected to achieve revenues of 5.29 billion, 6.70 billion, and 8.48 billion RMB for the years 2025, 2026, and 2027 respectively, with year-on-year growth rates of 24.51%, 26.67%, and 26.66% [6][7]. - The net profit attributable to the parent company is projected to be 1.30 billion, 1.69 billion, and 2.20 billion RMB for the same years, with growth rates of 28.31%, 29.70%, and 30.32% [6][7]. - The company maintains a leading position in the pelvic rehabilitation field and has diversified its rehabilitation product lines, supporting the "Buy" rating [6]. Financial Performance Summary - In 2024, the company achieved a revenue of 4.25 billion RMB (yoy +24.57%) and a net profit of 1.02 billion RMB (yoy +13.10%) [8]. - For Q1 2025, the company reported a revenue of 1.18 billion RMB (yoy +13.36%) and a net profit of 0.40 billion RMB (yoy +9.85%) [8]. - The company's consumables and accessories revenue reached 1.19 billion RMB in 2024, showing a year-on-year increase of 26.21% [8]. Profitability and Margins - The gross margin for the medical device business in 2024 is 74.47%, with the main business gross margin at 72.25% [8]. - The net profit margin is reported at 25.65%, reflecting a decrease due to lower gross margins and increased operating expenses [8]. Future Outlook - The company is actively exploring potential applications in cutting-edge fields such as brain-machine interfaces and AI skin health assessment, indicating a strategic focus on innovation and growth [8].